Pictet Asset Management
DNLI icon

Pictet Asset Management’s Denali Therapeutics DNLI Stock Holding History

Pictet Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.9M Buy
2,791,206
+232,341
+9% +$4.77M 0.07% 267
2026
Q1 		$48.4M Buy
2,558,865
+1,229,757
+93% +$24.5M 0.05% 315
2025
Q4 		$22M Buy
1,329,108
+829,946
+166% +$14M 0.02% 514
2025
Q3 		$7.25M Buy
499,162
+84,050
+20% +$1.21M 0.01% 741
2025
Q2 		$5.85M Buy
415,112
+71,153
+21% +$1M 0.01% 764
2025
Q1 		$5.06M Buy
343,959
+324,603
+1,677% +$6.22M 0.01% 799
2024
Q4 		$394K Buy
19,356
+2,806
+17% +$71.8K ﹤0.01% 1494
2024
Q3 		$482K Buy
16,550
+2,754
+20% +$68.3K ﹤0.01% 1343
2024
Q2 		$320K Hold
13,796
– – ﹤0.01% 1495
2024
Q1 		$283K Sell
13,796
-425,422
-97% -$8M ﹤0.01% 1572
2023
Q4 		$9.43M Sell
439,218
-150,281
-25% -$2.98M 0.01% 653
2023
Q3 		$12.2M Buy
+589,499
New +$15M 0.02% 585

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management's DNLI Position: Q2 2026 in Review

Pictet Asset Management increased its Denali Therapeutics (DNLI) stake by 9.1% in Q2 2026, buying an estimated $4.77M and bringing the position to 2,791,206 shares worth $71.9M. The position accounts for 0.07% of the portfolio, ranked #267.

Pictet Asset Management first reported a position in DNLI in Q3 2023 and has held it in 12 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Pictet Asset Management held 2,791,206 shares of Denali Therapeutics worth $71.9M as of Q2 2026.
  • Pictet Asset Management bought 232,341 Denali Therapeutics shares in Q2 2026, an estimated $4.77M.
  • Denali Therapeutics made up 0.07% of Pictet Asset Management's portfolio in Q2 2026, its #267 holding.
  • Pictet Asset Management first reported a position in Denali Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.